BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...
Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...
The newest case is the fifth to bring similar allegations against Moderna in the same court, with three others, all filed Nov ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback